B cell targeting by molecular adjuvants for enhanced immunogenicity.
Expert Rev Vaccines
; 19(11): 1023-1039, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-948588
ABSTRACT
INTRODUCTION:
Adjuvants are critical components of vaccines to improve the quality and durability of immune responses. Molecular adjuvants are a specific subclass of adjuvants where ligands of known immune-modulatory receptors are directly fused to an antigen. Co-stimulation of the B cell receptor (BCR) and immune-modulatory receptors through this strategy can augment downstream signaling to improve antibody titers and/or potency, and survival in challenge models. AREAS COVERED C3d has been the most extensively studied molecular adjuvant and shown to improve immune responses to a number of antigens. Similarly, tumor necrosis superfamily ligands, such as BAFF and APRIL, as well as CD40, CD180, and immune complex ligands can also improve humoral immunity as molecular adjuvants. EXPERT OPINION However, no single strategy has emerged that improves immune outcomes in all contexts. Thus, systematic exploration of molecular adjuvants that target B cell receptors will be required to realize their full potential as next-generation vaccine technologies.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines
/
B-Lymphocytes
/
Adjuvants, Immunologic
Type of study:
Prognostic study
/
Systematic review/Meta Analysis
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Expert Rev Vaccines
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
14760584.2020.1857736
Similar
MEDLINE
...
LILACS
LIS